Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, will announce its financial results for the second quarter and first half ended June 30, 2026, on August 12 before U.S. markets open. The company will host a conference call at 8:30am ET to discuss the results and answer investor questions. Kamada focuses on growing through its proprietary specialty plasma products, distribution partnerships, plasma collection operations in the U.S., and strategic mergers and acquisitions. This update is important for investors tracking the company's progress in expanding its product portfolio and plasma business.
VICI Properties is rated a Buy with a $30 price target, offering a potential 26% price increase plus an 8% dividend yield. The company maintains strong fundamentals including full occupancy, triple-net leases, and a long average lease term of nearly ...
QXO, Inc. is currently trading below its book value and at a market capitalization less than its recent acquisition of TopBuild, despite building a leading platform in building products distribution. The company reported a 70% year-over-year revenue ...
eBay CEO Jamie Iannone has sold company shares worth $2.3 million. This sale comes as eBay's stock has delivered a 12% return over the past year. The move may reflect personal financial planning or confidence in the company's current valuation. Inves...
PEPE, a meme coin, gained 15.4% over the past week, reaching $0.00000393 as of September 20, 2026. Despite rumors of whale buying, a fund launch, and a token buyback, no solid evidence supports these claims, which mostly appear as promotional content...
Bitcoin's 50-day moving average recently crossed above its 200-day average, a pattern known as a golden cross often seen as a buy signal. Historical data since 2014 shows that Bitcoin's price rose 90 days after eight out of eleven golden crosses, ave...
